CytomX Therapeutics Sees Stock Rise on Successful Funding and Clinical Progress

CytomX Therapeutics shares are trading higher after the company announced a $100 million underwritten offering of common stock and reported positive interim data in their Phase 1 study for CX-2051 in advanced colorectal cancer.